根据美国证券交易委员会(SEC)披露，摩根士丹利递交了截止至2025年3月31日的第一季度持仓报告(13F)。 据统计，摩根士丹利第一季度持仓总市值为1.4万亿美元，上一季度总市值为1.43万亿美元，环比下降2.1%。该基金在第一季度的投资组合中新增了444只个 股，增持了3493只个股，减持了3410只个股，清仓了323只个股。其中前十大持仓标的占总市值的19.97%。 | 2025-03-31 | | | --- | --- | | 13F Activity | | | Market Value | $1.40t, Prior: $1.43t | | Inflows (Outflows) as % of Total MV | +1.5021% | | New Purchases | 444 stocks | | Added To | 3493 stocks | | Sold out of | 323 stocks | | Reduced holdings in | 3410 stocks | | Top 10 Holdings % | 19.97% | | Turnover %(1) | 9.12% | ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering and subsequent merger with AbbVie Inc. [1] Group 1: Class Action Details - The class action lawsuit is on behalf of individuals or entities that sold or disposed of Cerevel's common stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [3] - The deadline for shareholders to register for the class action is June 3, 2025, and there is no cost to participate [5] Group 2: Allegations Against Cerevel - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering documents omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which artificially deflated Cerevel's stock price [4] - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially depressed price while possessing nonpublic information about AbbVie's interest, leading to a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [4] Group 3: Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights and ensuring companies adhere to responsible business practices [6]

Core Insights - AbbVie has received FDA accelerated approval for its antibody-drug conjugate, telisotuzumab vedotin (Emrelis), for treating certain patients with non-small cell lung cancer (NSCLC) [1][2] - Emrelis is the first FDA-approved therapy for adult patients with locally advanced or metastatic, non-squamous NSCLC with high c-Met protein overexpression who have received prior systemic therapy [2] - The approval is based on data from the phase II LUMINOSITY study, which demonstrated a 35% overall response rate in patients with high c-Met protein overexpression [5] Company Developments - Emrelis marks a significant milestone for AbbVie as it is the company's first internally developed solid tumor drug and its first solid tumor therapy approved for lung cancer [4] - AbbVie has expanded its oncology portfolio to five therapies, including Imbruvica, Venclexta, Epkinly, Elahere, and Emrelis [8] - The company is also developing another c-Met targeting ADC, Temab-A, for metastatic colorectal cancer and gastroesophageal cancer [10] Pipeline and Collaborations - AbbVie is conducting a phase III confirmatory study called TeliMET NSCLC-01 to convert the accelerated approval of Emrelis into a full approval [5] - The company has entered into a collaboration with ADARx Pharmaceuticals to develop small interfering RNA (siRNA) therapeutics across multiple disease areas [11] - AbbVie will make an upfront payment of $335 million to ADARx, with potential milestone payments reaching several billion dollars [13]

Core Viewpoint - The lawsuit against Cerevel Therapeutics Holdings, Inc. alleges that the company and its controlling shareholder, Bain Capital, engaged in misleading practices regarding a secondary stock offering and the subsequent acquisition by AbbVie, resulting in significant financial losses for shareholders [2]. Group 1: Allegations and Financial Impact - Cerevel's October 16, 2023 secondary stock offering documents allegedly omitted material facts about AbbVie's interest in acquiring Cerevel at a price significantly higher than the offering price of $22.81 per share, which artificially deflated Cerevel's stock price until the merger announcement [2]. - Bain Capital acquired shares during the October Offering at an artificially depressed price while allegedly possessing nonpublic information about AbbVie's acquisition interest, leading to a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [2]. - Cerevel's January 18, 2024 Proxy statement is claimed to have misled investors regarding the nature and timing of AbbVie's interest in the company [2]. Group 2: Class Action Details - The class period for the lawsuit includes shareholders who sold or disposed of Cerevel stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [1]. - The deadline for shareholders to register for the class action is June 3, 2025, and there is no cost or obligation to participate [3]. - Registered shareholders will receive updates through portfolio monitoring software throughout the lifecycle of the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].

Core Viewpoint - Citi has upgraded the stock rating for Regeneron Pharmaceuticals (REGN.US) while downgrading AbbVie (ABBV.US) due to the differing impacts of recent U.S. government policies on these pharmaceutical giants [1][3] Group 1: Regulatory Changes - President Trump signed an executive order to implement a "Most Favored Nation" pricing model, linking U.S. drug prices to lower prices in other developed countries [2][3] - The executive order aims to eliminate subsidies for foreign healthcare and reduce drug prices for U.S. citizens by ensuring they pay the lowest prices available globally [2] Group 2: Company Ratings and Price Targets - Citi analyst Geoff Meacham upgraded Regeneron's stock rating from "Neutral" to "Buy," citing manageable policy risk exposure and strong product pipeline in melanoma treatments [3][4] - Regeneron's target price was raised from $600 to $700 per share, reflecting a favorable risk-reward ratio after a 55% decline from its 2024 peak [4] - AbbVie's stock rating was downgraded from "Buy" to "Neutral," with a target price reduced from $205 to $188 per share, due to increased policy risk exposure and a relatively weaker product pipeline [4][5] Group 3: Market Reactions - The announcement of the executive order initially negatively impacted global pharmaceutical stocks, particularly European companies [1][2] - Regeneron's stock closed at $571.36, while AbbVie's stock closed at $177.44, indicating market adjustments following the news [4][5]

Core Viewpoint - The article discusses the investment potential of AbbVie Inc. and Pfizer Inc., highlighting the importance of independent research in generating actionable investment ideas [1]. Group 1 - AbbVie Inc. and Pfizer Inc. were previously analyzed in March 2024, indicating ongoing interest in these companies [1]. - The investment style promoted emphasizes providing clear and actionable insights, which aligns with the needs of investors seeking reliable information [1]. Group 2 - The service mentioned claims to have helped its members outperform the S&P 500 while avoiding significant losses during periods of high market volatility [2]. - A trial membership is offered to potential investors to assess the effectiveness of the investment strategies employed [2].

Company Overview - AbbVie has a strong leadership team with key executives including Jeff Stewart (EVP and Chief Commercialization Officer), Roopal Thakkar (EVP and R&D, Chief Scientific Officer), and Scott Reents (EVP and CFO) [1][2] Current Challenges - The company is experiencing some disruption due to external factors such as MFN (Most Favored Nation) policies and tariffs, which are impacting operational timelines [3][4] - There is an ongoing discussion about the level of disruption and the time it is taking to adapt to these changes, indicating that the company is actively involved in contingency planning [3][4]

AbbVie (ABBV) 2025 Conference Summary Company Overview - **Company**: AbbVie (ABBV) - **Date of Conference**: May 14, 2025 - **Key Speakers**: - Jeff Stewart, Executive Vice President, Chief Commercialization Officer - Rupl Thacker, Executive Vice President, R&D Chief Scientific Officer - Scott Rantz, Executive Vice President, Chief Financial Officer Key Points and Arguments Industry and Market Dynamics - **Disruption and Contingency Planning**: AbbVie acknowledges some disruption due to external factors but emphasizes that it is not affecting business execution. The management team is actively involved in contingency planning and assessing implications of changes in the market [4][6][9]. - **Drug Pricing Policies**: The company is taking the potential impact of new executive orders on drug pricing seriously, indicating that they are closely monitoring developments and preparing for various scenarios [6][8][9]. - **Pricing Equalization**: AbbVie believes that the concept of equalizing drug prices between the US and Europe is complex and may not be feasible due to different healthcare systems and pricing controls in Europe [10][11][12]. Financial Performance and Projections - **Revenue Guidance**: AbbVie has increased its revenue guidance for SKYRIZI and RINVOQ to a combined $31 billion by 2027, with SKYRIZI expected to generate $20 billion and RINVOQ $11 billion [55][56]. - **Immunology Market**: The immunology segment remains a significant revenue driver, with expectations of continued growth despite pricing pressures. The company anticipates low single-digit price degradation over the next five years [51][53]. Research and Development - **M&A Strategy**: AbbVie has been active in M&A, completing over 25 transactions since early 2024, focusing on filling its pipeline in neuroimmunology and oncology [31][32]. - **Obesity Market Entry**: AbbVie has entered the obesity market through a licensing deal with Gubra for an amylin compound, highlighting the potential for differentiation and long-term market opportunities [33][39]. Competitive Landscape - **Direct-to-Consumer Advertising**: AbbVie is the largest DTC advertiser in the pharmaceutical industry. The company is prepared to pivot its marketing strategies if regulations on DTC advertising are imposed [19][21][23]. - **Oral vs. Injectable Therapies**: AbbVie believes that while oral therapies are emerging, injectable products like SKYRIZI and RINVOQ will remain insulated from significant competition due to their efficacy and convenience [64]. Other Important Insights - **Tariffs and Supply Chain**: AbbVie is monitoring the potential impact of tariffs on its supply chain and is implementing mitigation strategies to ensure product availability [26][28][29]. - **Market Growth in Obesity**: The obesity market is expected to grow significantly, with AbbVie anticipating a cash pay component that will support its aesthetics business [48]. Conclusion AbbVie is strategically navigating a complex pharmaceutical landscape with a focus on maintaining growth through innovation, M&A, and effective contingency planning. The company is well-positioned to address challenges related to drug pricing, market competition, and regulatory changes while capitalizing on emerging opportunities in the obesity market and maintaining its leadership in immunology.

Core Insights - AbbVie announced the accelerated approval of EMRELIS™ (telisotuzumab vedotin-tllv) by the FDA for treating adult patients with advanced non-squamous non-small cell lung cancer (NSCLC) who have high c-Met protein overexpression and have received prior systemic therapy [1][2][3] - Lung cancer remains the leading cause of cancer-related deaths globally, with approximately 85% classified as NSCLC [2][3] - The approval is based on the overall response rate (ORR) and duration of response (DOR) from the Phase 2 LUMINOSITY study, which showed a 35% ORR and a median DOR of 7.2 months in patients with high c-Met overexpression [2][3] Company Overview - EMRELIS is AbbVie's first internally developed solid tumor medicine and represents a significant step in their commitment to developing cancer therapies [2][3] - The company is expanding its antibody-drug conjugate (ADC) portfolio to deliver targeted therapies to patients with difficult-to-treat tumors [2][3] - AbbVie is also focused on patient access, offering support programs to reduce out-of-pocket costs for eligible patients [6][21] Industry Context - The c-Met protein is overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients, with about half of these patients having high c-Met overexpression [2][3] - There is a critical unmet need for targeted therapies in this patient population, as they often face poor prognosis and limited treatment options [2][3] - The FDA has also approved the Roche VENTANA® MET (SP44) RxDx Assay as a companion diagnostic to identify patients eligible for EMRELIS treatment [4][3]

Shares of key drugmakers like Eli Lilly (LLY) , Pfizer (PFE) , Merck (MRK) , AbbVie (ABBV) , Gilead, Bristol-Myers, Amgen (AMGN) and several other U.S. pharmaceutical stocks were in the green at market close on Monday. The stocks recovered well from their pre-market decline on Monday in response to President Trump's social media post, which stated that the government will sign an executive order later in the day that will result in a 30% to 80% decrease in prescription drug prices in the United States. The ...